Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in chronic allograft nephropathy with C4d or B-cell/plasma cell infiltration
2006-006137-41Phase 2Completed
- Sponsor
- Technical University of Munich
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in Chronic Allograft Kidney Disease (CKaD) and kidney allograft rejection (2 arms), sponsored by Technical University of Munich. Primary endpoint: Serum creatinine level at 12 months. Started Mar 2007; status: completed.
02
Drugs
rituximab
03
Conditions
Chronic Allograft Kidney Disease (CKaD)kidney allograft rejection
Beyond the preview
Go deeper on 2006-006137-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006137-41.